Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

De novo mutations in childhood cases of sudden unexplained death that disrupt intracellular Ca 2+ regulation
Halvorsen, Matthew , Gould, Laura , Grant, Gariel, Moya, Raquel , Ackerman, Michael J. , Tester, David J. , Maurano, Matthew T. , Goldstein, David B. , Lin, Peter T. , Tsien, Richard W , Devinsky, Orrin , Wang, Xiaohan , Rabin, Rachel , Pappas, John , Devinsky, Orrin

Mayo Clinic

Proceedings of the National Academy of Sciences | December 20, 2021 | Volume: 118 | Issue: 52 | Pages: No page available

10.1073/pnas.2115140118 | PMID 34930847 Get It

Significance Approximately 400 United States children 1 y of age and older die suddenly from unexplained causes annually. We studied whole-exome sequence data from 124 “trios” (decedent child and living parents) to identify genetic risk factors. Nonsynonymous mutations, mostly de novo (present in child but absent in both biological parents), were highly enriched in genes associated with cardiac and seizure disorders relative to controls, and contributed to 9% of deaths. We found significant overtransmission of loss-of-function or pathogenic missense variants in cardiac and seizure disorder genes. Most pathogenic variants were de novo in origin, highlighting the importance of trio studies. Many of these pathogenic de novo mutations altered a protein network regulating calcium-related excitability at submembrane junctions in cardiomyocytes and neurons.
Family Conflict and Older Chinese Americans’ Self-Efficacy in End-of-Life Care Planning: The Role of Acculturation
Wang, Kaipeng , Liu, Yanqin , Fries, Carson De, Sun, Fei , Fries, Carson M. De

Mayo Clinic

Innovation in Aging | December 17, 2021 | Volume: 5 | Issue: Supplement_1 | Pages: 569-570

10.1093/geroni/igab046.2188 Get It

Abstract Family involvement in end-of-life (EOL) care is critical to ensure older adults’ health and quality of life. Older adults’ self-efficacy in discussing EOL care plans with family members can facilitate family involvement in EOL care planning. Research shows that family relationships are associated with self-efficacy in discussing EOL care with family members among older Chinese Americans. However, the roles of family conflict and acculturation remain unknown. This study examines the association between family conflict and self-efficacy in discussing EOL care with family members and whether such an association differs by acculturation levels among older Chinese Americans. Data were collected from 207 Chinese Americans aged 65-102 in two metropolitan areas in 2017. Ordinary least squares regression was conducted to examine the association between family conflict, acculturation, and self-efficacy in discussing EOL care with family. Family conflict was negatively associated with older adults’ self-efficacy in discussing EOL care with family. More specifically, the negative association between family conflict and self-efficacy in discussing EOL care with family members was more pronounced for those with higher levels of acculturation. Findings highlighted differential effects of family conflict on self-efficacy of EOL care plan discussion for older adults with different acculturation levels. Those with higher acculturation may be more independent in their EOL care planning and aware of the possible negative effects of family conflict in their EOL care planning discussions. Acculturation needs to be considered by geriatric health providers to develop family-centered interventions in improving end-of-life care planning for this population.
Studying APOE ɛ4 Allele Dose Effects with a Univariate Morphometry Biomarker
Wang, Gang, Initiative, for the Alzheimer’s Disease Neuroimaging, Zhou, Wenju, Kong, Deping, Qu, Zongshuai, Ba, Maowen, Hao, Jinguang, Yao, Tao, Dong, Qunxi, Su, Yi, Reiman, Eric M., Caselli, Richard J., Chen, Kewei, Wang, Yalin, Wang, Gang, Initiative, for the Alzheimer’s Disease Neuroimaging, Zhou, Wenju, Kong, Deping, Qu, Zongshuai, Ba, Maowen, Hao, Jinguang, Yao, Tao, Dong, Qunxi, Su, Yi, Reiman, Eric M., Caselli, Richard J., Chen, Kewei, Wang, Yalin

Mayo Clinic

Journal of Alzheimer's Disease | December 17, 2021 | Volume: 85 | Issue: 3 | Pages: 1233-1250

10.3233/jad-215149 | PMID 34924383 Get It

Background: A univariate neurodegeneration biomarker (UNB) based on MRI with strong statistical discrimination power would be highly desirable for studying hippocampal surface morphological changes associated with APOE ɛ4 genetic risk for AD in the cognitively unimpaired (CU) population. However, existing UNB work either fails to model large group variances or does not capture AD induced changes. Objective: We proposed a subspace decomposition method capable of exploiting a UNB to represent the hippocampal morphological changes related to the APOE ɛ4 dose effects among the longitudinal APOE ɛ4 homozygotes (HM, N = 30), heterozygotes (HT, N = 49) and non-carriers (NC, N = 61). Methods: Rank minimization mechanism combined with sparse constraint considering the local continuity of the hippocampal atrophy regions is used to extract group common structures. Based on the group common structures of amyloid-β (Aβ) positive AD patients and Aβ negative CU subjects, we identified the regions-of-interest (ROI), which reflect significant morphometry changes caused by the AD development. Then univariate morphometry index (UMI) is constructed from these ROIs. Results: The proposed UMI demonstrates a more substantial statistical discrimination power to distinguish the longitudinal groups with different APOE ɛ4 genotypes than the hippocampal volume measurements. And different APOE ɛ4 allele load affects the shrinkage rate of the hippocampus, i.e., HM genotype will cause the largest atrophy rate, followed by HT, and the smallest is NC. Conclusion: The UMIs may capture the APOE ɛ4 risk allele-induced brain morphometry abnormalities and reveal the dose effects of APOE ɛ4 on the hippocampal morphology in cognitively normal individuals.
Whole genome sequencing–based copy number variations reveal novel pathways and targets in Alzheimer's disease
Chen, Ming , Wang, Minghui , Neff, Ryan , Wang, Erming , Reddy, Joseph S. , Allen, Mariet , Ertekin‐Taner, Nilüfer , Jager, Philip L. De , Bennett, David A. , Haroutunian, Vahram , Schadt, Eric E. , Ming, Chen , Bennett, David A. , Wang, Qian , Shen, Qi , Wang, Xue, Zhang, Bin

Mayo Clinic

Alzheimer's & Dementia | December 17, 2021 | Volume: 18 | Issue: 10 | Pages: 1846-1867

10.1002/alz.12507 | PMID 34918867 Get It

AbstractIntroductionA few copy number variations (CNVs) have been reported for Alzheimer's disease (AD). However, there is a lack of a systematic investigation of CNVs in AD based on whole genome sequencing (WGS) data.MethodsWe used four methods to identify consensus CNVs from the WGS data of 1,411 individuals and further investigated their functional roles in AD using the matched transcriptomic and clinicopathological data.ResultsWe identified 3,012 rare AD‐specific CNVs whose residing genes are enriched for cellular glucuronidation and neuron projection pathways. Genes whose mRNA expressions are significantly correlated with common CNVs are involved in major histocompatibility complex class II receptor activity. Integration of CNVs, gene expression, and clinical and pathological traits further pinpoints a key CNV that potentially regulates immune response in AD.DiscussionWe identify CNVs as potential genetic regulators of immune response in AD. The identified CNVs and their downstream gene networks reveal novel pathways and targets for AD.
145: A DESCRIPTIVE STUDY OF COVID-19 PATIENTS IN SKILLED NURSING FACILITIES IN ALL 50 U.S. STATES
Ahmad, Sumera , Biehl, Michelle, Wang, Stanley , Menges, Jason, Boman, Karen , Kumar, Vishakha K. , Sharma, Mayank Kumar , Kashyap, Rahul

Mayo Clinic

Critical Care Medicine | December 16, 2021 | Volume: 50 | Issue: 1 | Pages: 56-56

10.1097/01.ccm.0000806904.71416.7c Get It

Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma
Karime, Christian , Wang, Jing , Woodhead, Gregory , Mody, Kabir , Hennemeyer, Charles , Mahadevan, Daruka , Chandana, Sreenivasa R , Borad, Mitesh J. , Babiker, Hani M.

Mayo Clinic

Expert Opinion on Investigational Drugs | December 16, 2021 | Volume: 31 | Issue: 1 | Pages: 1-13

10.1080/13543784.2022.2019706 | PMID 34913781 Get It

An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
León, José de , Schoretsanitis, Georgios , Smith, Robert L. , Molden, Espen , Solismaa, Anssi , Seppälä, Niko , Kopeček, Miloslav , Švancer, Patrik , Olmos, I. Cánovas , Ricciardi, Carina , García, Celso Iglesias , Iglesias-Alonso, Ana , Ruan, Can‐Jun , Wang, Chuanyue , Wang, Gang , Tang, Yi‐lang , Kim, Yong Sik , Kim, Se Hyun , Rajkumar, Anto P. , González‐Esquivel, Dinora F. , Jung–Cook, Helgi , Verdoux, Hélène , Quilès, Clélia , Sanz, Emílio J. , Cuevas, Carlos De las , Cohen, Dan , Schulte, Peter F.J. , Yağcıoğlu, A. Elif Anıl , Chopra, Nitin , McCollum, Betsy , Shelton, Charles , Cotes, Robert O. , Kaithi, Arun R., Kane, John M. , Farooq, Saeed , Ng, Chee H. , Bilbily, John , Hiemke, Christoph , López‐Jaramillo, Carlos , McGrane, Ian R. , Lana, Fernando , Arrojo, Manuel , Rădulescu, Flavian Ștefan , Seifritz, Erich , Every‐Palmer, Susanna , Bebawi, Emmanuel , Bhattacharya, Rahul , Kelly, Deanna L. , Otsuka, Yuji , Lazáry, Judit , Torres, Rafael , Yécora, Agustín, Motuca, Mariano , Chan, Sherry Kit Wa , Berardis, Domenico De , Adebayo, Richard A. , Кирилочев, О.О. , Soloviev, A. G. , Fountoulakis, Konstantinos Ν. , Wilkowska, Alina , Cubała, Wiesław Jerzy , Ayub, Muhammad , Silva, Alzira , Bonelli, Raphael M., Crespo‐Facorro, Benedicto , Temmingh, Henk , Decloedt, Eric , Pedro, Maria Rosel , Tsukahara, Masaru , Gründer, Gerhard , Čelofiga, Andreja , Ristić, Dragana Ignjatović , Ortiz, Bruno Bertolucci , Elkis, Hélio , Siskind, Dan , Masmoudi, R. , Saffian, Shamin Mohd , Leung, Jonathan G. , Buckley, P.F. , Freudenreich, Oliver , Müller, Daniel J. , de Leon, Jose , Olmos, Ismael , Iglesias-Garcia, Celso , Spina, Edoardo , Ruan, Can-Jun , Wang, Chuan-Yue , Tang, Yi-Lang , Lin, Shih-Ku , Lane, Hsien-Yuan , Kim, Yong Sik , Kim, Se Hyun , Rajkumar, Anto P , González-Esquivel, Dinora F , Jung-Cook, Helgi , Baptista, Trino , Rohde, Christopher , Nielsen, Jimmi , Verdoux, Hélène , Quiles, Clelia , Sanz, Emilio J , De Las Cuevas, Carlos , Cohen, Dan , Schulte, Peter F J , Ertuğrul, Aygün , Anıl Yağcıoğlu, A Elif , Chopra, Nitin , McCollum, Betsy , Shelton, Charles , Cotes, Robert O , Kane, John M , Farooq, Saeed , Ng, Chee H , Bilbily, John , Hiemke, Christoph , López-Jaramillo, Carlos , McGrane, Ian , Lana, Fernando , Eap, Chin B , Every-Palmer, Susanna , Bousman, Chad A , Bebawi, Emmanuel , Bhattacharya, Rahul , Kelly, Deanna L , Otsuka, Yuji , Lazary, Judit , Motuca, Mariano , Chan, Sherry K W , Zolezzi, Monica , Ouanes, Sami , De Berardis, Domenico , Grover, Sandeep , Procyshyn, Ric M , Adebayo, Richard A , Kirilochev, Oleg O , Soloviev, Andrey , Fountoulakis, Konstantinos N , Wilkowska, Alina , Cubała, Wiesław J , Ayub, Muhammad , Silva, Alzira , Villagrán-Moreno, José M , Crespo-Facorro, Benedicto , Temmingh, Henk , Decloedt, Eric , Pedro, Maria R , Takeuchi, Hiroyoshi , Tsukahara, Masaru , Gründer, Gerhard , Sagud, Marina , Celofiga, Andreja , Ignjatovic Ristic, Dragana , Ortiz, Bruno B , Elkis, Helio , Pacheco Palha, António J , LLerena, Adrián , Fernandez-Egea, Emilio , Siskind, Dan , Weizman, Abraham , Masmoudi, Rim , Mohd Saffian, Shamin , Leung, Jonathan G , Buckley, Peter F , Marder, Stephen R , Citrome, Leslie , Freudenreich, Oliver , Correll, Christoph Ulrich , Müller, Daniel J , Kopecek, Miloslav , Arrojo-Romero, Manuel , Schoretsanitis, Georgios , Rohde, Christopher , Nielsen, Jimmi , Bousman, Chad , LLerena, Adrián , Citrome, Leslie

Mayo Clinic

Pharmacopsychiatry | December 15, 2021 | Volume: 55 | Issue: 02 | Pages: 73-86

10.1055/a-1625-6388 | PMID 34911124 Get It

Abstract This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas’ original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300–600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75–150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175–300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100–200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250–400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150–300 mg/day, and 6) in the US with ancestries other than from Asia or the original people from the Americas with average clozapine metabolism needing 300–600 mg/day. Baseline and weekly CRP monitoring for at least four weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration.
Inflammatory pseudotumor mimicking chronic pulmonary embolism or pulmonary artery sarcoma: Report of five cases
Liao, Xiaoyan , Bojanowski, Christine M. , Yen, Andrew , Kerr, Kim M. , Dumouchel, Justin, Auger, William R. , Madani, Michael M. , Wang, Huan‐You , Yi, Eunhee S. , Lin, Grace , Liao, Xiaoyan , Yen, Andrew, Pretorius, Victor

Mayo Clinic

Pulmonary Circulation | December 15, 2021 | Volume: 12 | Issue: 1 | Pages: No page available

10.1002/pul2.12004 | PMID 35506111 Get It

AbstractInflammatory pseudotumor (IPT), also known as plasma cell granuloma, is a rare lesion of unknown etiology that occurs in many organs, especially in the lung. Here we report five cases of IPT arising in pulmonary artery mimicking chronic thromboembolic disease, not previously documented in the literature. Those cases were identified at our institute among over 2500 pulmonary endarterectomy (PEA) specimens acquired from 2000 to 2017. The cohort included three men and two women with a median age of 41 years (range: 23–54). All patients presented with dyspnea and radiologic findings of pulmonary artery thromboembolism, some concerning for intimal sarcoma. The duration between disease onset and PEA ranged from 6 months to approximately 3 years. Histologically, all cases showed proliferation of spindle cells with marked inflammatory infiltrates composed predominantly of plasma cells, histiocytes, and small lymphocytes. Ancillary studies were performed in each case and ruled out other possibilities, such as sarcoma, lymphoma, plasmacytoma, IgG4‐related disease, and infection. IPT arising in pulmonary artery presenting clinically as acute or chronic thromboembolic disease is very unusual, in which clinical data, radiographic findings, and histopathologic features have to be integrated for reaching the proper diagnosis.
The prospective association between periodontal disease and brain imaging outcomes: The Atherosclerosis Risk in Communities study
Adam, Hamdi S , Lakshminarayan, Kamakshi , Wang, Wendy , Norby, Faye L. , Meyer, Katie A. , Hughes, Timothy M. , Pankow, James S. , Wong, Dean F. , Jack, Clifford R. , Lutsey, Pamela L. , Beck, Jim, Demmer, Ryan T. , Jack, Clifford R , Lutsey, Pamela L , Pankow, James S , Demmer, Ryan T , Mosley, Thomas H. , Walker, Keenan A. , Gottesman, Rebecca F. , Sen, Souvik

Mayo Clinic

Journal of Clinical Periodontology | December 15, 2021 | Volume: 49 | Issue: 4 | Pages: 322-334

10.1111/jcpe.13586 | PMID 34905804 Get It

AbstractAimWe investigate if periodontal disease is prospectively associated with cerebrovascular and neurodegenerative markers of dementia and Alzheimer's pathology.Materials and MethodsN = 1306 participants (Visit 5 mean age = 76.5 [standard deviation = 5.4] years) in the Atherosclerosis Risk in Communities study with completed dental exams at Visit 4 underwent brain magnetic resonance imaging scans at Visit 5 while N = 248 underwent positron emission tomography scans. Participants were classified as edentulous or, among the dentate, by the modified Periodontal Profile Class. Brain volumes were regressed on periodontal status in linear regressions. Cerebrovascular measures and β‐amyloid positivity were regressed on periodontal status in logistic regressions.ResultsPeriodontal disease was not associated with brain volumes, microhaemorrhages, or elevated β‐amyloid. Compared with periodontally healthy individuals, odds ratios [95% confidence interval] for all‐type infarcts were 0.37 [0.20, 0.65] for severe tooth loss and 0.56 [0.31, 0.99] for edentulous participants.ConclusionsWithin the limitations of this study, periodontal disease was not associated with altered brain volumes, microhaemorrhages, or β‐amyloid positivity. Tooth loss was associated with lower odds of cerebral infarcts.
Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?
Vizza, Carmine Dario , Benza, Raymond L. , White, R. James , Adir, Yochai , Andreassen, Arne K., Balasubramanian, Vijay , Bartolome, Sonja, Carlsen, Jørn , Camacho, Rafael Enrique Conde, Ford, H. James , Humbert, Marc , Naeije, Robert , Orfanos, Stylianos E. , Oudiz, Ronald J. , Perrone, Sergio V. , Shlobin, Oksana A. , Torres, Fernando , Vachiéry, Jean Luc, Wang, Kuo‐Yang , Liu, Yan , Golden, Gil, Matsubara, Hiromi , Benza, Raymond L. , Oudiz, Ronald , Lang, Iréne , Badagliacca, Roberto , Rosenkranz, Stephan , Andreassen, Arne K., Blanco, Isabel , Bourge, Robert C. , Camacho, Rafael Enrique Conde , D’Alto, Michele , Farber, Harrison W. , Frantz, Robert P. , Ghio, Stefano , Gomberg‐Maitland, Mardi , Simon, Marc A. , Sitbon, Olivier , Vachiéry, Jean‐Luc , Yacoub, Magdi Habib

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | December 14, 2021 | Volume: 205 | Issue: 7 | Pages: 751-760

10.1164/rccm.202109-2079pp | PMID 34905704 Get It

Abstract Despite numerous therapeutic advances in pulmonary arterial hypertension, patients continue to suffer high morbidity and mortality, particularly considering a median age of 50 years. This article explores whether early, robust reduction of right ventricular afterload would facilitate substantial improvement in right ventricular function and thus whether afterload reduction should be a treatment goal for pulmonary arterial hypertension. The earliest clinical studies of prostanoid treatment in pulmonary arterial hypertension demonstrated an important link between lowering mean pulmonary arterial pressure (or pulmonary vascular resistance) and improved survival. Subsequent studies of oral monotherapy or sequential combination therapy demonstrated smaller reductions in mean pulmonary arterial pressure and pulmonary vascular resistance. More recently, retrospective reports of initial aggressive prostanoid treatment or initial combination oral and parenteral therapy have shown marked afterload reduction along with significant improvements in right ventricular function. Some data suggest that reaching threshold levels for pressure or resistance (components of right ventricular afterload) may be key to interrupting the self-perpetuating injury of pulmonary vascular disease in pulmonary arterial hypertension and could translate into improved long-term clinical outcomes. Based on these clues, the authors postulate that improved clinical outcomes might be achieved by targeting significant afterload reduction with initial oral combination therapy and early parenteral prostanoids.